Journal of Clinical Psychopharmacology
February 1, 2001
Alex Gamma, Alfred Buck, Thomas Berthold et al.
84 citations
The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of the underlying neurophysiologic substrate. The authors compared mood and...
Pediatric Emergency Care
October 1, 2000
Michael H Shannon
51 citations
Ecstasy (MDMA) is an amphetamine derivative of growing popularity. The drug produces a range of toxicities when taken either in standard doses or overdose. In overdose it has major toxicity, producing several different life-threatening manifestations. Hepatotoxicity and hyponatremia are common but poorly understood consequences of MDMA overdose. The drug can produce long-term, if not permanent,...
September 26, 2000
Stella Pereira De Almeida
1 citation
O presente estudo teve como objetivo identificar os padrões de uso de "êxtase"na cidade de São Paulo.Os usuários foram recrutados através da técnica de amostragem snowball, também utilizada para o recrutamento do grupo controle, composto de indivíduos com estilo de vida semelhante aos primeiros mas que nunca haviam experimentado "êxtase"(não usuários).Usuários (52) e não usuários (52) foram...
Psychopharmacology
September 7, 2000
M. Morgan
Abstract. Rationale: Recreational use of "ecstasy" (3,4-methylenedioxymethamphetamine; MDMA) has become increasingly widespread. Until recently, however, little was known about the possible persistent psychological effects of extensive use of this drug. Objective: The aim of the present review is to evaluate recent empirical evidence concerning the persistent psychological sequelae of...
Sleep
September 1, 2000
Tore Nielsen, L Laberge, J Paquet et al.
Study objectives: This work assesses the prevalence and development of disturbing dreams among adolescents and the association of these dreams with anxiety. Design: Sex differences in prevalence were analyzed with chi-square analyses. Changes over time were assessed with Wilcoxon tests and cross-tabulation tables. Associations with anxiety and DSM-III-R symptoms were assessed with ANOVA...
Psychosomatic Medicine
September 1, 2000
Michael Speca, Linda E. Carlson, Eileen Goodey et al.
1,091 citations
OBJECTIVE: The objective of this study was to assess the effects of participation in a mindfulness meditation-based stress reduction program on mood disturbance and symptoms of stress in cancer outpatients. METHODS: A randomized, wait-list controlled design was used. A convenience sample of eligible cancer patients enrolled after giving informed consent and were randomly assigned to either an...
Annals of the New York Academy of Sciences
September 1, 2000
Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al.
44 citations
Abstract MDMA (3,4‐methylenedioxymethamphetamine) use can cause neurochemical, behavioral and endocrine alterations, similar to those produced by exposure to acute stress, suggesting its potential as a “chemical stressor.” It is known that stressful stimuli can produce a depression of immune function and an alteration in immune cells distribution. In vitro exposure to MDMA resulted in a...
Annals of the New York Academy of Sciences
September 1, 2000
Deborah C. Mash, Craig A. Kovera, John Pablo et al.
146 citations
Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term...
Biological Psychiatry
May 1, 2000
M Tomitaka, S Tomitaka, S Rajdev et al.
N-Methyl-D-aspartate (NMDA) receptor antagonists, including phencyclidine (PCP) and dizocilpine (MK801), cause schizophrenialike psychosis in humans, and produce vacuolated neurons in the cingulate and retrosplenial cortices of the rat brain. Since psychotically depressed patients and schizophrenic depressed patients may require treatment with selective serotonin reuptake inhibitors (SSRIs), it...
Fortschritte der Neurologie-Psychiatrie
March 2000
Nico J Diederich, V Pieri, Christopher G Goetz
Visual hallucinations (VH) are seen in about a third of all patients with Parkinson's disease (PD) and are usually considered to be an early marker or clinical component of a dopaminergic psychosis. Their peculiar phenomenology has not yet been studied in a systematic manner. A semi-structured interview was performed twice in 62 PD patients. Different motoric and cognitive disease scales were...